Last reviewed · How we verify
Early palliative care integration
Early palliative care integration is a Small molecule drug developed by University Hospital, Clermont-Ferrand. It is currently in Phase 3 development for Advanced cancer (metastatic or locally advanced disease), Serious life-limiting illnesses managed in hospital settings.
Early palliative care integration is a clinical intervention model that incorporates palliative care principles alongside curative treatment from early disease stages rather than as a late-stage alternative.
Early palliative care integration is a clinical intervention model that incorporates palliative care principles alongside curative treatment from early disease stages rather than as a late-stage alternative. Used for Advanced cancer (metastatic or locally advanced disease), Serious life-limiting illnesses managed in hospital settings.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Early palliative care integration |
|---|---|
| Sponsor | University Hospital, Clermont-Ferrand |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This approach combines symptom management, psychosocial support, and advance care planning with standard oncologic or disease-modifying therapies from diagnosis or early treatment phases. The intervention aims to improve quality of life, reduce suffering, and enhance patient-centered decision-making throughout the disease trajectory, rather than reserving palliative care for end-of-life settings.
Approved indications
- Advanced cancer (metastatic or locally advanced disease)
- Serious life-limiting illnesses managed in hospital settings
Common side effects
Key clinical trials
- Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology (NA)
- Feasibility Trial of ScarWork for Post-breast Surgery Pain Syndrome. (NA)
- Effects of Early Palliative Care Integration on Patients With Newly Diagnosed Multiple Myeloma (NA)
- Integrated Supportive and Palliative Care for Older Adults in the ICU (NA)
- Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study. (PHASE2)
- Effectiveness of Early Intervention in Palliative Care for Acute Myeloid Leukemia Patients Comparing to Standard of Care (NA)
- Standard Care With or Without Early Palliative Care Provided by Palliative Care Specialist in Advanced Non-small Cell Lung Cancer Patients (NA)
- Early Palliative Care for Patients with Oral Cancer in Sri Lanka (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Early palliative care integration CI brief — competitive landscape report
- Early palliative care integration updates RSS · CI watch RSS
- University Hospital, Clermont-Ferrand portfolio CI
Frequently asked questions about Early palliative care integration
What is Early palliative care integration?
How does Early palliative care integration work?
What is Early palliative care integration used for?
Who makes Early palliative care integration?
What development phase is Early palliative care integration in?
Related
- Manufacturer: University Hospital, Clermont-Ferrand — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Advanced cancer (metastatic or locally advanced disease)
- Indication: Drugs for Serious life-limiting illnesses managed in hospital settings
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing